"
Team:SupBiotech-Paris/Concept
From 2009.igem.org
(Difference between revisions)
Enguerrand (Talk | contribs) |
Enguerrand (Talk | contribs) |
||
| Line 24: | Line 24: | ||
| width="34%" | | | width="34%" | | ||
Cellulaire | Cellulaire | ||
| - | | width=" | + | | width="50%" | |
Très Bon | Très Bon | ||
| width="34%" | | | width="34%" | | ||
| Line 39: | Line 39: | ||
| width="34%" | | | width="34%" | | ||
Cellulaire | Cellulaire | ||
| - | | width=" | + | | width="50%" | |
Faible | Faible | ||
| width="34%" | | | width="34%" | | ||
| Line 54: | Line 54: | ||
| width="34%" | | | width="34%" | | ||
Tissulaire | Tissulaire | ||
| - | | width=" | + | | width="50%" | |
Nulle | Nulle | ||
| width="34%" | | | width="34%" | | ||
| Line 69: | Line 69: | ||
| width="34%" | | | width="34%" | | ||
Cellulaire | Cellulaire | ||
| - | | width=" | + | | width="50%" | |
Moyen | Moyen | ||
| width="34%" | | | width="34%" | | ||
| Line 83: | Line 83: | ||
| width="34%" | | | width="34%" | | ||
Cellulaire | Cellulaire | ||
| - | | width=" | + | | width="50%" | |
Faible | Faible | ||
| width="34%" | | | width="34%" | | ||
Revision as of 12:38, 14 October 2009
Project
Introduction Current therapies Gene therapies DVS Concept Tissue Vector Cell Vector Therapeutic plasmid Conclusion Implementation Tissue targeting Antitumor action Treatment modeling Conclusion
Ressources
BioBricks Material & Method Bibliography
Ethics & Safety
| Stabilité | Toxicité | Ciblage | Passage des membranes | Résistance au Syst. Immun. | Industrialisation | |
|---|---|---|---|---|---|---|
|
Virus |
Bonne |
Forte |
Cellulaire |
Très Bon |
Nulle |
Difficile |
|
Phage |
Bonne |
Faible |
Cellulaire |
Faible |
Nulle |
Facile |
|
Bactérie |
Bonne |
Faible/Forte |
Tissulaire |
Nulle |
Faible/Forte |
Facile |
|
Nanoparticule lipidique |
Faible |
Faible |
Cellulaire |
Moyen |
Faible |
Moyenne |
|
Bonne |
Moyenne |
Cellulaire |
Faible |
Faible |
Moyenne |
